Metrics to compare | 300642 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300642PeersSector | |
|---|---|---|---|---|
P/E Ratio | 262.1x | 29.1x | −0.4x | |
PEG Ratio | −4.30 | −1.05 | 0.00 | |
Price/Book | 2.2x | 2.8x | 2.6x | |
Price / LTM Sales | 8.2x | 5.8x | 3.0x | |
Upside (Analyst Target) | - | 29.2% | 57.5% | |
Fair Value Upside | Unlock | 18.1% | 7.8% | Unlock |
Tellgen Corporation research, development, production, and sales of in-vitro diagnostic products in China and internationally. The company offers fully automatic flow fluorescence analyzer and CLIA analyzer; molecular test such as HPV test, lung cancer, colon cancer, personalized medicine, and infertility; and automatic integrated gene detection systems. It also provides tumor detection products; HPV nucleic acid testing products; methylation mutation detection products; detection products for invasive fungal diseases. The company was founded in 2003 and is based in Shanghai, China.